Find disease awareness content and relevant supporting materials

Later weekday of surgery seems to affect the prognosis adversely in oesophageal cancer, whereas any such influence on other cancer sites is unknown. This study aimed to test whether weekday of surgery influenced...

Severe weight loss is experienced by patients with eating difficulties after surgery for oesophageal cancer. The aim of this prospective cohort study was to assess the influence of eating difficulties and severe weight loss...

The UK's National Institute for Health and Care Excellence (NICE) has recommended Opdivo (nivolumab), from Bristol Myers Squibb, as a treatment for certain resected oesophageal or gastro-oesophageal junction (GEJ) patients.

The principal research question is to determine whether a randomised controlled trial comparing induction chemotherapy followed by oesophagectomy and induction...

Background: A temporary ileostomy may reduce symptoms from anastomotic leakage after rectal cancer resection. Earlier results of the EASY trial showed that early closure of the temporary ileostomy was associated with significantly fewer postoperative complications.

The single most distressing symptom for more than 70% of patients with oesophageal cancer is difficulty in swallowing (dysphagia) caused...

About 7500 patients are diagnosed with oesophageal cancer each year in the UK of which less than a quarter have...

Bristol Myers Squibb announced that checkpoint inhibitor treatment Opdivo (nivolumab) demonstrated its efficacy in the phase III CheckMate-577 trial involving patients with oesophageal or gastroesophageal junction cancers who had previously received neoadjuvant chemoradiation therapy and tumour resection.

This ESMO Clinical Practice Guideline provides key recommendations for managing oesophageal cancer.

To assess whether gefitinib will improve overall survival in patients with oesophageal cancer when compared to a placebo.